# Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil

> **NCT05630313** · — · UNKNOWN · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 100 (estimated)

## Conditions studied

- Vaccine-induced Thrombotic Thrombocytopenia Syndrome
- Guillain-Barre Syndrome
- Acute Disseminated Encephalomyelitis
- Transverse Myelitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05630313
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-04
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630313, "Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05630313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*